Vimarsana
Biggest News Aggregation in the World

Page 34 - Basic Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Basic Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Basic Research Today - Breaking & Trending Today

Department of Defense Announces Fiscal Year 2021 Defense Established Program to Stimulate Competitive Research (DEPSCoR) Awards - Vimarsana News

Department of Defense Announces Fiscal Year 2021 Defense Established Program to Stimulate Competitive Research (DEPSCoR) Awards

The DoD announced today $14.6 million in DEPSCoR awards to 23 collaborative teams following two FY2021 competitions.  DEPSCoR is a capacity-building program that is designed to strengthen the basic research infrastructure at institutions of higher education in under-utilized states/territories.

InMed Expands Patent Portfolio with Novel Cannabinoid - Vimarsana News

InMed Expands Patent Portfolio with Novel Cannabinoid

Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER,...

Think bigger and build on basic research, Chinese scientist says - Vimarsana News

Think bigger and build on basic research, Chinese scientist says

Astrophysicist asks whether Chinese people can really be confident if their textbooks are based on work from the West.

Source: scmp.com
AIM ImmunoTech Provides Summary of Ampligen® Data - Vimarsana News

AIM ImmunoTech Provides Summary of Ampligen® Data

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors ...

AIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade Therapies - Vimarsana News

AIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampligen Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with